This post is a guest contribution by Niels Jensen*, chief executive partner of London-based Absolute Return Partners.

It is time to move on. Not that the crisis is over, by no stretch of the imagination. But it is not going to make one iota of difference if I join the blame game bandwagon. It is what it is. Allow me instead to focus my energy on what is likely to happen next. That is more productive and definitely more useful.

A can of worms We are dealing with a rather large can of worms. The lid is off and the worms are all over the place. Let’s focus on what these worms might be up to. For all the

In this business tv show, join international business experts Ian Coleman, Partner, Head of emerging markets, PricewaterhouseCoopers UK, Tony Dickel, CEO, MRI China, and Chris Runckel, President, Runckel and Associates, as they talk about upcoming issues they see for businesses operating in emerging economies.

Ian Coleman: I think that what we have seen is a growing change to one of acceptance that it isn’t novel, its business as usual. A growing change towards the integration of emerging market managers into the managerial structures of multi international companies because the importance of doing business in those countries.

Tony Dickel: You’ve got the 1billion US dollars a week of foreign investment, you’ve got the 3000 companies a month, you’ve got the 10% economic growth, all an environment of an emerging population of only children, there isn’t a hope in hell that demographically China can create enough middle management and senior management over the next …

Cryolife, Inc. (CRY), headquartered in both Atlanta, Georgia and San Mateo, California, processes and distributes implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The company recently announced the receipt of a CE Mark for the use of CryoLife’s BioGlue Surgical Adhesive for periosteal fixation following a brow lift. The CE Mark approval is a visible declaration by the manufacturer or representative that the equipment complies with all the requirements of the applicable European Union (EU) directives.

The adhesive will be distributed by the company’s partner, BioForm Medical, for use in approved cosmetic and reconstructive plastic surgery in the EU. The product will be marketed under the name “BioGlue Aesthetic™ Medical Adhesive.” CryoLife will be the exclusive supplier of BioGlue for all cosmetic and plastic surgery applications under the terms of the agreement with BioForm.

According to Steven Basta, chief